Dilated Cardiomyopathy Therapeutic Market Size

Dilated Cardiomyopathy Therapeutic Market Analysis

The Dilated Cardiomyopathy Therapeutic Market is projected to register a CAGR of 3.6% during the forecast period.

The COVID-19 pandemic had a significant impact on dilated cardiomyopathy therapeutics market. For instance, according to an article titled 'A case of Dilated Cardiomyopathy in COVID-19,' published in May 2022, comparing cardiac cases in COVID-19 to respiratory cases, cardiac injury was documented in 19.7% to 29.8% of instances. Numerous pathways have contributed to the involvement of the cardiac myocardium in COVID-19, and up to 20-30% of hospitalized patients exhibit this involvement, as seen by high troponin levels. Similarly, in an article titled 'Prevalence, Characteristics, and Outcomes of COVID-19-Associated Acute Myocarditis,' published in April 2022, between 2.4 and 4.1 out of 1000 patients hospitalized for COVID-19 are thought to experience AM. Hence, this is likely to create more demand for dilated cardiomyopathy therapeutics during the pandemic. However, the postponed treatment procedures and surgeries resumed worldwide, driving the market's growth during the post-pandemic period. Therefore, the high number of heart treatment procedures and operations being performed is expected to boost the growth of the dilated cardiomyopathy therapeutics market during the forecast period.

The major factors attributing to the growth of the dilated cardiomyopathy therapeutics market are the increasing prevalence of heart diseases and increasing drug and alcohol abuse. For instance, according to an article published by the National Library of Medicine, in May 2022, around 1.5 million cases of myocarditis occur each year in the entire world. The incidence rate is often calculated as 10 to 20 cases per 100,000 people. Also, according to an article published in 2022, alcohol-induced toxicity leads to non-ischemic dilated cardiomyopathy characterized by loss of contractile function and dilatation of myocardial ventricles. Hence, alcohol use is an important cause of non-ischemic cardiomyopathy and accounts for 10% of all cases of dilated cardiomyopathies. Additionally, according to an article published by Wolters Kluwer, in January 2022, alcohol-induced cardiomyopathy is a type of acquired dilated cardiomyopathy caused by long-term heavy alcohol consumption. It also stated that the prevalence of alcohol-induced cardiomyopathy among patients with heart failure (HF) or dilated cardiomyopathy depends on the threshold alcohol consumption used to identify alcohol-induced cardiomyopathy.

Furthermore, as per an article published by ScienceDirect, in June 2022, substantial proportions of youth surveyed had tried illicit drugs at least once in the countries such as Australia (greater than 40%), Canada (greater than35%), Europe (greater than 23% boys, 17% girls), United States (greater than 40%, more than 25% of 8th graders and nearly half of the 12th graders in the United States reported smoking marijuana daily, and 1 in 7 reported having been a daily marijuana smoker at some time for at least a month. Alcohol use disorder is a common disorder in the United States. The 12-month prevalence of alcohol use disorder is estimated to be 4.6% among 12 to 17-year-olds and 8.5% among adults aged 18 years and older in the United States. Rates of the disorder are greater among adult men (12.4%) than among adult women (4.9%). Twelve-month prevalence of alcohol use disorder among adults decreases in middle age, being greatest among 18 to 29-year-olds (16.2%) and lowest among individuals aged 65 years and older (1.5%). Furthermore, the increasing number of people suffering from cardiac muscle infections, along with drug or alcohol abuse, are also the major factors that help in driving the growth of the market.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However side effects of dilated cardiomyopathy therapeutics are expected to hinder the market growth over the forecast period.